Abstract

A disclosure-ready principle is most effective when embedded within clinical trial design and document authoring processes from the beginning, rather than relying on late-stage redaction. Medical writers, regulatory professionals and other cross-functional contributors must balance the accurate reporting of study design with the needs of regulatory assessment, operational execution and public disclosure. Early consideration of disclosure requirements can help limit the inclusion of avoidable personal data, redundant content, disclosure-sensitive information and non-essential commercially confidential information, reducing downstream disclosure challenges.

The proposed three-step lifecycle structure in this article offers a practical way to move disclosure readiness from a retrospective compliance activity to an embedded authoring and review discipline.